CA2039491A1 - Stable compositions for parenteral administration and method of making same - Google Patents

Stable compositions for parenteral administration and method of making same

Info

Publication number
CA2039491A1
CA2039491A1 CA002039491A CA2039491A CA2039491A1 CA 2039491 A1 CA2039491 A1 CA 2039491A1 CA 002039491 A CA002039491 A CA 002039491A CA 2039491 A CA2039491 A CA 2039491A CA 2039491 A1 CA2039491 A1 CA 2039491A1
Authority
CA
Canada
Prior art keywords
parenteral administration
making same
stable compositions
mixture
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002039491A
Other languages
French (fr)
Other versions
CA2039491C (en
Inventor
William Steber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of CA2039491A1 publication Critical patent/CA2039491A1/en
Application granted granted Critical
Publication of CA2039491C publication Critical patent/CA2039491C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Abstract

The invention relates to certain stable microsphere compositions suitable for parenteral administration containing a fat or wax or mixture thereof; a biologically active protein, peptide or polypeptide; and an oil, semi-soft fat, fatty acid derivative or mixture thereof. The invention also relates to a method of making the microsphere compositions.
CA002039491A 1990-03-30 1991-03-28 Stable compositions for parenteral administration and method of making same Expired - Lifetime CA2039491C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/502,382 1990-03-30
US07/502,382 US5213810A (en) 1990-03-30 1990-03-30 Stable compositions for parenteral administration and method of making same

Publications (2)

Publication Number Publication Date
CA2039491A1 true CA2039491A1 (en) 1991-10-01
CA2039491C CA2039491C (en) 2001-09-04

Family

ID=23997559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002039491A Expired - Lifetime CA2039491C (en) 1990-03-30 1991-03-28 Stable compositions for parenteral administration and method of making same

Country Status (29)

Country Link
US (1) US5213810A (en)
EP (1) EP0448930B1 (en)
JP (1) JP2966564B2 (en)
KR (1) KR0159778B1 (en)
CN (1) CN1063941C (en)
AR (1) AR248085A1 (en)
AT (1) ATE106240T1 (en)
AU (1) AU641994B2 (en)
BG (1) BG60850B1 (en)
CA (1) CA2039491C (en)
CZ (1) CZ283053B6 (en)
DE (1) DE69102176T2 (en)
DK (1) DK0448930T3 (en)
ES (1) ES2054380T3 (en)
FI (1) FI101676B1 (en)
HK (1) HK1000004A1 (en)
HU (1) HU219584B (en)
IE (1) IE65970B1 (en)
IL (1) IL97145A (en)
MX (1) MX172602B (en)
NO (1) NO300717B1 (en)
NZ (1) NZ237509A (en)
PL (1) PL167692B1 (en)
PT (1) PT97160B (en)
RO (1) RO106191B1 (en)
RU (1) RU2011377C1 (en)
SK (1) SK279461B6 (en)
YU (1) YU47650B (en)
ZA (1) ZA912398B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134873T1 (en) * 1991-07-23 1996-03-15 American Cyanamid Co STABLE COMPOSITIONS FOR PARENTERAL ADMINISTRATION AND USE THEREOF
US5599660A (en) * 1993-01-19 1997-02-04 Pharmacia Biotech Inc. Method and preparation for sequential delivery of wax-embedded, inactivated biological and chemical reagents
WO1994017106A1 (en) * 1993-01-19 1994-08-04 Pharmacia P-L Biochemicals, Inc. Storage and delivery of purified protein reagents with carrier wax
US6083430A (en) * 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
JP2002522354A (en) * 1997-09-19 2002-07-23 シャイア ラボラトリーズ，インコーポレイテッド Solid solution beadlets
AU2002300572B2 (en) * 1997-09-19 2004-11-25 Shire Laboratories, Inc. Solid Solution Beadlet
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
TR200103188T2 (en) * 1999-05-07 2002-04-22 Pharmasol Gmbh Lipid particles based on liquid and solid lipid mixtures.
US8663692B1 (en) * 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
DK1187601T3 (en) * 1999-06-07 2005-11-21 Altana Pharma Ag A novel composition and form of administration comprising an acid-labile proton pump inhibitor
US6544646B2 (en) 2000-04-27 2003-04-08 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
NZ523741A (en) * 2000-06-26 2004-10-29 Martek Biosciences Corp Improved methods of incorporating polyunsaturated fatty acids in milk
WO2002026372A2 (en) 2000-09-27 2002-04-04 Verion Inc. Instant water dissolvable encapsulate and process
ATE392887T1 (en) * 2000-10-10 2008-05-15 Wyeth Corp STABILIZED MEDICINAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION
FR2852843B1 (en) 2003-03-24 2008-05-23 Karim Ioualalen GALENIC SYSTEM FOR MASKING TASTE
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
JP2007513145A (en) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク Method for producing pharmaceutical fine particles
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053653A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
BRPI0417338A (en) * 2003-12-04 2007-04-17 Pfizer Prod Inc multiparticulate azithromycin dosage forms by liquid-based processes
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8299025B2 (en) 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US8221809B2 (en) * 2006-06-22 2012-07-17 Martek Biosciences Corporation Encapsulated labile compound compositions and methods of making the same
KR101200728B1 (en) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 Osmotic delivery system and piston assemblies
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
JP5744735B2 (en) 2008-09-04 2015-07-08 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc Sustained release formulation using non-aqueous carrier
JP5494957B2 (en) 2009-06-11 2014-05-21 株式会社リコー Toner for developing electrostatic image, developer, image forming method and image forming apparatus
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9364549B2 (en) * 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US20160151286A1 (en) * 2013-05-29 2016-06-02 Therakine Biodelivery Gmbh Hydrophilic Microparticles, Drug-Delivery Material, Method For Manufacturing Thereof And Methods For Delivery of A Drug-Delivery Composition
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
BR112018073511A2 (en) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. glucagon receptor selective polypeptides and methods of use
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
JP2022522114A (en) * 2019-02-21 2022-04-14 クロマデックス，インコーポレイテッド Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compound, and nicotinyl riboside compound derivative in the formulation.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
CH637297A5 (en) * 1978-12-05 1983-07-29 Nestle Sa MICROBALL COMPRISING A MICROORGANISM AND ITS MANUFACTURING METHOD.
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
DE3024416C2 (en) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Process for the production of medicaments with sustained release of active substances
US4666839A (en) * 1982-12-01 1987-05-19 Amgen Methods and materials for obtaining microbial expression of polypeptides including bovine prolactin
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4755387A (en) * 1985-03-21 1988-07-05 The Procter & Gamble Company Therapeutic particles
DE3527356A1 (en) * 1985-07-31 1987-02-05 Degussa METHOD FOR IMPROVING THE FERTILITY OF PETS
SE462894B (en) * 1985-10-28 1990-09-17 Biogram Ab MICROCAPPLES, PROCEDURES FOR PREPARING THEREOF AND USING
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles

Also Published As

Publication number Publication date
FI911531A0 (en) 1991-03-28
YU47650B (en) 1995-12-04
AU641994B2 (en) 1993-10-07
IL97145A (en) 1996-06-18
DE69102176T2 (en) 1995-01-05
AR248085A1 (en) 1995-06-30
US5213810A (en) 1993-05-25
CZ283053B6 (en) 1997-12-17
YU57091A (en) 1994-01-20
ZA912398B (en) 1992-01-29
HU911054D0 (en) 1991-10-28
NO911228L (en) 1991-10-01
CA2039491C (en) 2001-09-04
PT97160A (en) 1991-11-29
FI101676B (en) 1998-08-14
SK279461B6 (en) 1998-11-04
PL289657A1 (en) 1992-01-13
HK1000004A1 (en) 1997-10-03
DK0448930T3 (en) 1994-06-20
NO300717B1 (en) 1997-07-14
KR910016322A (en) 1991-11-05
PL167692B1 (en) 1995-10-31
PT97160B (en) 1998-07-31
JP2966564B2 (en) 1999-10-25
RO106191B1 (en) 1993-03-31
CN1055293A (en) 1991-10-16
RU2011377C1 (en) 1994-04-30
EP0448930A1 (en) 1991-10-02
NO911228D0 (en) 1991-03-26
HUT59834A (en) 1992-07-28
CN1063941C (en) 2001-04-04
JPH04221319A (en) 1992-08-11
IE911041A1 (en) 1991-10-09
FI911531A (en) 1991-10-01
BG60850B1 (en) 1996-05-31
KR0159778B1 (en) 1998-12-01
IE65970B1 (en) 1995-11-29
ES2054380T3 (en) 1994-08-01
EP0448930B1 (en) 1994-06-01
NZ237509A (en) 1993-04-28
MX172602B (en) 1993-01-03
ATE106240T1 (en) 1994-06-15
FI101676B1 (en) 1998-08-14
AU7397291A (en) 1991-10-03
IL97145A0 (en) 1992-05-25
DE69102176D1 (en) 1994-07-07
HU219584B (en) 2001-05-28

Similar Documents

Publication Publication Date Title
CA2039491A1 (en) Stable compositions for parenteral administration and method of making same
EP0177368A3 (en) A novel drug delivery system and method of preparation thereof
CA2009890A1 (en) Valproic acid
HUT51254A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
CA2005143A1 (en) Stabilized hydrophobic protein formulations of g-csf
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
MX9502034A (en) Stable, lyophilized formulation, comprising a protein and dispensing equipment.
AU3829089A (en) Fr901228 substance and preparation thereof
EP1025840A3 (en) Oral drug compositions and methods
FI945619A (en) Liquid preparations containing cyclosporine and a process for their preparation
CA2094540A1 (en) Orally-ingestible nutrition compositions having improved palatability
HUT48609A (en) Process for producing kumaran derivatives and pharmaceutical compositions comprising same as active ingredient
WO1994001006A3 (en) Composition for use as a food or food supplement
IL84765A (en) 9-(1-carboxy-3-(guanidinophenyl)propylamino)octahydro-10-oxo-6h-pyridazo(1,2-a)-(1,2)diazepine-1-carboxylic acids and esters,their preparation and pharmaceutical compositions containing them and some intermediates therefor
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
IE831226L (en) Method for preparing 26,26,26,27,27,27-hexafluoro-1ó,25-¹dihydrocholestrol
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
HUP9903459A3 (en) Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
IL81800A0 (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo(or oxo)-5-pyrimidine-carboxylic acids and esters and pharmaceutical compositions containing the same
EP0225020A3 (en) Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of vip
HUT46851A (en) Process for producing improves pharmaceutical compositions containing flunarazine
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
HUT55598A (en) Fungicidal composition comprising new amino acid amide derivatives as active ingredient and process for producing the active ingredients
HUT50844A (en) Process for producing new 2'-halogen methylidene, 2'-ethenylidene and 2'-ethinyladenosine derivatives and pharmaceutical compositions comprising same as active ingredient
HUT49370A (en) Process for producing polypeptides and pharmaceutical compositions comprising same as active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202